EUVIMEDEUVIMED entdecken
Open Access

Ultramutagenesis through Combined Msh2 Depletion and Proofreading-Deficient DNA Polymerase ε Expression Enhances Small-Molecule Target Identification in Forward Genetic Screens

Alexander-Hoi Nguyen, Vicky Li, Wei-Min Chen, Jacob Kimberg, Anthony J Davis, David G McFadden iD, Juan Manuel Povedano iD

ACS Chemical Biology · 2026

DOI: 10.1021/acschembio.6c00605 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Chemical Biology, 2026. Verfasst von Alexander-Hoi Nguyen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Endocrinology, UT Southwestern Medical Center, Dallas, Texas75390, United States. Hauptthemen laut MEDLINE: MutS Homolog 2 Protein, DNA Polymerase II, Mutagenesis. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NASA, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

DNA mismatch repair (MMR) deficiency has been widely utilized in forward genetic screens to identify drug resistance mutations and elucidate the mechanisms of action of cytotoxic small molecules. However, MMR deficiency generates a characteristic mutational signature enriched for C > T transitions that precludes saturation of mutagenesis. We hypothesized that expression of proofreading-deficient DNA polymerase epsilon, as has been observed in patients with biallelic MMR deficiency, would enhance mutagenesis and enable identification of new resistance mutations and cytotoxin mechanisms. Here, we combine auxin-inducible degradation of Msh2 with doxycycline-inducible expression of the proofreading-deficient PolεP286R mutant in murine small cell lung cancer (SCLC) cells. Simultaneous MMR deficiency and mutant Polε expression markedly increased the emergence of bortezomib-resistant clones relative to either perturbation alone, and targeted sequencing of Psmb5 in bortezomib-resistant clones identified recurrent mutations previously reported in resistance screens using MMR-deficient cells and chemical mutagenesis. We next applied this platform to investigate resistance to lurbinectedin, a clinically relevant therapy for SCLC. Whole-exome sequencing revealed recurrent loss-of-function alterations in nucleotide excision repair (NER) genes, most notably Ercc5 and Ercc4, implicating NER deficiency as a major mechanism of lurbinectedin resistance and supporting a central role for NER in mediating lurbinectedin-induced cytotoxicity. Collectively, these findings establish inducible ultramutagenesis as a powerful and versatile platform for the unbiased discovery of drug resistance mechanisms and therapeutic vulnerabilities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MutS Homolog 2 ProteinDNA Polymerase IIMutagenesisAnimalsBortezomibMiceCell Line, TumorDrug Resistance, NeoplasmDNA Mismatch RepairMutationGenetic TestingProteasome Endopeptidase ComplexHumans

Substanzen

MutS Homolog 2 ProteinDNA Polymerase IIBortezomibMsh2 protein, mouseProteasome Endopeptidase Complex

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Endocrinology, UT Southwestern Medical Center, Dallas, Texas75390, United States.
  • Department of Biochemistry, UT Southwestern Medical Center, Dallas, Texas75390, United States.
  • Department of Radiation Oncology, Section of Molecular Medicine, UT Southwestern Medical Center, Dallas, Texas75390, United States.
  • Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas75235, United States.

ORCID-Profile: David G McFadden, Juan Manuel Povedano

Förderung

  • NCI NIH HHS
  • NASA
  • NINDS NIH HHS
  • U.S. Department of Energy
  • National Cancer Institute
  • National Institute of Neurological Disorders and Stroke
  • National Aeronautics and Space Administration

Zitieren

APA

Nguyen, A. H., Li, V., Chen, W. M., Kimberg, J., Davis, A. J., McFadden, D. G., & Povedano, J. M. (2026). Ultramutagenesis through Combined Msh2 Depletion and Proofreading-Deficient DNA Polymerase ε Expression Enhances Small-Molecule Target Identification in Forward Genetic Screens. ACS Chemical Biology. https://doi.org/10.1021/acschembio.6c00605

Vancouver

Nguyen AH, Li V, Chen WM, Kimberg J, Davis AJ, McFadden DG, et al. Ultramutagenesis through Combined Msh2 Depletion and Proofreading-Deficient DNA Polymerase ε Expression Enhances Small-Molecule Target Identification in Forward Genetic Screens. ACS Chemical Biology. 2026. doi:10.1021/acschembio.6c00605

BibTeX
@article{Nguyen2026,
  author = {Nguyen, Alexander-Hoi and Li, Vicky and Chen, Wei-Min and Kimberg, Jacob and Davis, Anthony J and McFadden, David G and Povedano, Juan Manuel},
  title = {Ultramutagenesis through Combined Msh2 Depletion and Proofreading-Deficient DNA Polymerase ε Expression Enhances Small-Molecule Target Identification in Forward Genetic Screens},
  journal = {ACS Chemical Biology},
  year = {2026},
  doi = {10.1021/acschembio.6c00605}
}
Kostenlos starten →